Aumolertinib as first-line treatment for EGFR-mutated non-small cell lung cancer:A real-world study
10.3781/j.issn.1000-7431.2025.2403-0169
- VernacularTitle:阿美替尼一线治疗EGFR突变型非小细胞肺癌的真实世界研究
- Author:
Mingyuan GUO
1
;
Xiaoman DUAN
;
Haitao WANG
;
Jun ZHU
;
Yu ZHANG
;
Yanbin ZHAO
Author Information
1. 哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江 哈尔滨 150081
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Epidermal growth factor receptor;
Molecular targeted therapy;
Brain metastases;
First-line treatment
- From:
Tumor
2025;45(1):35-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of almonertinib,a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI),as a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer(NSCLC)in the real-world clinical practise,and to systematically analyze the independent risk factors influencing their prognosis.Methods:This retrospective cohort study enrolled 73 patients with EGFR-mutated advanced NSCLC who received first-line treatment with aumolertinib from April 1,2020 to December 31,2021.Survival curves were generated by using the Kaplan-Meier method,and intergroup comparisons were performed via log-rank test.Univariate and multivariate analyses of prognostic factors were conducted by using the COX proportional hazards regression model,with a focus on identifying prognostic factors in the subgroup of baseline brain metastases.Results:Among 73 patients,the median progression-free survival(mPFS)was 19.4 months,and the disease control rate(DCR)was 93.2%.Multivariate COX regression analysis revealed that central nervous system(CNS)metastasis status,EGFR mutation subtype,ECOG performance status(PS)score,and gender might be independent risk factors for PFS.Among 33 patients with baseline brain metastases,combined almonertinib with radiotherapy or bevacizumab,maximum diameter of brain metastases(≥3 cm),and ECOG PS score might be independent risk factors of PFS.Conclusion:This first real-world study confirms that aumolertinib demonstrates favorable efficacy as first-line treatment for EGFR-mutated locally advanced or metastatic NSCLC patients,aligning with findings from phase Ⅲ clinical trials.For patients in subgroup of baseline brain metastases,combining almonertinib with radiotherapy or bevacizumab is recommended to optimize outcomes.
